natgillin/translations-raw huggingface dataset:
Can end lid according to claim 2, wherein the outer surface and the underside of the sealing attachment are in form and dimension complementary to a lid area formed by the inner surface of the ring-wall and by the upper side of the breaking-away area. 
Poklopac limenke u skladu s bilo kojim od patentnim zahtjevima 1 do 10, naznačen time što vanjska površina i donja strana (29) brtvenog spoja (25) su u obliku i s dimenzijama komplementarnim području poklopca koje oblikuju unutarnja površina prstenaste stijenke (11) i gornja strana područja kidanja (7).
1,1'-Carbonyldiimidazole (1.27 eq) is added, and the reaction is stirred at room temperature for 1 h. 
Doda se 1,1'-karbonildiimidazol (1,27 ekv.), a reakcijsku smjesu miješa 1 sat na sobnoj temperaturi.
A method of controlling diseases on useful plants or on propagation material thereof caused by phytopathogens, which comprises applying to the useful plants, the locus thereof or propagation material thereof a composition according to claim 1. 
Postupak nadzora bolesti na korisnim biljkama ili na njihovom materijalu za razmnožavanje uzrokovanih fitopatogenima, naznačen time da se sastoji od primjene pripravka iz zahtjeva 1 na korisne biljke, na njihov lokus ili na njihov materijal za razmnožavanje.
treating the basic flow leaving the filter in a precipitator, initially with ferric chloride and then with calcium hydroxide until arsenic precipitation is complete, 
arsenom zasićenog bazični tok u navedenom taložniku se obrađuje, isprva feri kloridom, a zatim kalcijevim hidroksidom dok se arsen posve ne istaloži, -
The antibody of claim 1 or 2 which is a chimeric rodent-human or a rodentized antibody. 
Antitijelo u skladu s patentnim zahtjevom 1 ili 2, naznačeno time, da je himerno antitijelo tipa glodavac-ljudsko ili rodentizirano antitijelo.
The method of clause8, wherein the first and second detector are immobilized on a conjugate region and wherein the conjugate region does not overlap with the test region of the surface. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što su prvi i drugi detektor imobilizirani na konjugatnom području i gdje se konjugatno područje ne preklapa s ispitivanim područjem površine.
The pharmaceutical composition for use according to claim 4, wherein the composition is in solid, semi-solid or liquid form. 
Farmaceutski sastav za uporabu prema zahtjevu 4, gdje je sastav u krutom, semi-krutom ili tekućem obliku.
A culture of recombinant host cells according to claim 9 or 10, or of recombinant host cells obtained by a method according to claim 13 or 14, producing a heterodimeric Ig-like molecule. 
Rekombinantne stanice domaćini u skladu s patentnim zahtjevom 14, ili rekombinantne stanice domaćini dobivene pomoću postupka u skladu s patentnim zahtjevom 16, koje proizvode najmanje dva različita antitijela.
a demodulator (r104) configured to demodulate the signal having the signal frame, from which the guard interval is deleted, by use of an Orthogonal Frequency Division MuItiplexing,OFDM, method; 
demodulator (r104) konfiguriran za demoduliranje signala koji nosi okvir signala pomoću ortogonalne modulacijske tehnike u frekvencijskoj domeni, OFDM;
The method according to claim 1, wherein the amisulpride is administered by oral, transdermal, sublingual or inhaled administration. The method according to claim 1, wherein the subject is a human. 
Amisulprid, namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačen time što se primjenjuje rektalnom, intranazalnom, bukalnom, oralnom, transdermalnom, sublingvalnom ili inhalacijskom primjenom.
[Item 13] A compound represented by formula (II), or a pharmaceutically acceptable salt thereof or a solvate thereof: 
Spoj, naznačen time, da je predstavljen formulom (Il), ili njegova farmaceutski prihvatljiva sol ili njegov solvat: iKennjska formula 4]
a crystalline zoledronic acid, DL-lysine, and water molecular complex characterized by an X-ray powder diffraction pattern comprising peaks at about 9.7, 10.8, 14.4, 18.9, 21.4 ±0.2 degrees two-theta; 
kristalni molekulski kompleks zoledronske kiseline, dl-lizina i vode, naznačen time što ima uzorak difrakcije rendgenskih zraka na prahu, sa maksimunima na otprilike 9,7, 10,8, 14,4, 18,9, 21,4 ± 0,2 °2θ;
A pharmaceutical composition as in Claim 1, comprising S-ketamine HCl; citric acid; disodium edetate; sodium hydroxide; and water. 
Farmaceutski sastav prema zahtjevu 1, koji obuhvaća S-ketamin HCI; limunsku kiselinu; dinatrijev edetat; natrijev hidroksid; i vodu.
The method of claim 1, wherein the therapeutically effective amount of crenolanib or a pharmaceutically acceptable salt thereof is administered at least one of continuously, intermittently, systemically, or locally. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 1, pri čemu se terapeutski djelotvorna količina crenolaniba ili njegove farmaceutski prihvatljive soli daje najmanje jednom kontinuirano, naizmjenično, sustavno ili lokalno.
A toothbrush according to claim 1 in which the head is rotatable about a first axis when undergoing the first brushing motion and independently about a second axis when undergoing the second brushing motion. 
Četkica za zube (10) sukladno zahtjevu 1 pri čemu je glava (12) rotatabilna oko prve osi kada prolazi prvi pokret četkanja 1 neovisno oko druge osi kada prolazi drugi pokret četkanja.
The composition as claimed in claim 7, wherein the complex mineral fertilizer is an NPK, NP, NK or PK complex. 
Smjesa u skladu s patentnim zahtjevom 6, naznačen time što je složeno mineralno gnojivo kompleks NPK, NP, NK ili PK.
The process according to any one of the preceding claims, wherein the steps (i) to (iii), optionally also the preparation of the compound of formula II', are carried out in one pot. 
Postupak prema zahtjevu 1 ili 2, naznačen time, da se koraci od (i) do (iii), prema potrebi također i proizvodnja spoja formule II', provode u jednolončanom postupku.
Unless otherwise indicated, the term “alkenyl” as used herein by itself or as part of another group refers to straight or branched chains of 2 to 20 carbons, preferably 2 to 12 carbons, and more preferably 2 to 8 carbons with one or more double bonds in the normal chain, such as vinyl, 2-propenyl, 3-butenyl, 2-butenyl, 4-pentenyl, 3-pentenyl, 2-hexenyl, 3-hexenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 3-octenyl, 3-nonenyl, 4-decenyl, 3-undecenyl, 4-dodecenyl, 4,8,12-tetradecatrienyl, and the like. 
Osim ako nije drugačije naznačeno, termin "alkenil" kao što se ovdje upotrebljava, samostalno ili kao dio druge skupine odnosi se na ravni ili razgranati lanac od 2 do 20 ugljika, poželjno 2 do 12 ugljika i još poželjnije 2 do 8 ugljikovih atoma sa jednom ili više dvostrukih veza u uobičajenom lancu, kao što su vinil, 2-propenil, 3-butenil, 2-butenil, 4-pentenil, 3-pentenil, 2-heksenil, 3-heksenil, 2-heptenil, 3-heptenil, 4-heptenil, 3-oktenil, 3-nonenil, 4-decenil, 3-undecenil, 4-dodecenil, 4,8,12-tetradekatrienil i slično.
The isolated nucleic acid of claim 20, wherein the variant AAV capsid protein, when present in an AAV virion, provides for increased infectivity of a photoreceptor cell by the AAV virion compared to the infectivity of a photoreceptor cell by an AAV virion comprising the corresponding parental AAV capsid protein. 
Izolirana nukleinska kiselina naznačena time što sadrži nukleotidnu sekvencu koja kodira varijantu kapsidnog proteina adeno-povezanog virusa (AAV), pri čemu je varijanta AAV kapsidnog proteina definirana kao u bilo kojem od zahtjeva 7 do 12.
The compound of claim 1, wherein the modified oligonucleotide comprises: 
g sekvenca nukleobaza modificiranog oligonukleotida je:
enucleating a swine oocyte; fusing the oocyte with a donor swine fibroblast cell, the genome of the fibroblast cell comprising at least one inactivated CD163 allele; and 
odstranjivanje svinjske jajne stanice spajanje jajne stanice s fibroblastičnom stanicom svinje davatelja, genom fibroblastične stanice, koji uključuje barem jednu deaktiviranu CD163 alelu; i aktiviranje jajne stanice za stvaranje embrija
"Heteroaryl" means a monocyclic or multicyclic aromatic ring system of about 5 to about 14 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is/are atoms other than carbon, for example nitrogen, oxygen or sulfur. 
"cikloalkil" znači nesupstituirani ili supstituirani, zasićeni, stabilni, nearomatski, kemijski izvediv karbociklički prsten s, po mogućnosti, 3 do 15 atoma ugljika; "heteroaril" znači monociklički ili policiklički aromatski prstenasti sustav s 5 do 14 atoma u prstenu, gdje jedan ili više atoma u prstenastom sustavu je/su atomi koji nisu ugljik.
X is a carboxylic acid or a derivative thereof, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, excipient or diluent, or any combination thereof. 
Farmaceutski sastav koji sadrži barem jedan lipidni spoj prema bilo kojem od zahtjeva 5 - 7, i farmaceutski prihvatljiv nosač, pomoćnu tvar ili razrjeđivač, 1li bilo koju njihovu kombinaciju.
The assembly according to claim 3, wherein said lubricant is a silicone based lubricant. 
Sklop u skladu s patentnim zahtjevom 3, naznačen time što navedeno sredstvo za podmazivanje je sredstvo za podmazivanje na bazi silikona.
Y is CH when Q is N; or Y is N when Q is CH; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof. 
Y je CH kada Q je N; ili Y je N kada Q je CH; ili njegova farmaceutski prihvatljiva sol, njegov enantiomer ili dijastereomer.
or a pharmaceutically acceptable salt or solvate thereof. The method of claim 5, wherein the cancer is deficient in Homologous Recombination (HR) dependent DNA double strand break (DSB) repair pathway. 
Spoj ili pripravak za primjenu prema zahtjevima od 12 do 16, naznačen time, što je rak deficitaran u pogledu puta popravka dvostrukog lančanog loma (DBS) DNK ovisnog o homolognoj rekombinaciji (HR).
The United States Pharmacopoeia (USP 26) classifies dimethyl polysiloxane into the group of antifoam additives. 
Američka farmakopeja (USP 26) stavlja dimetil polisiloksan u skupinu dodataka protiv stvaranja pjene.
A combination according to claim 4 wherein the corticosteroid is beclomethasone dipropionate. 
Kombinacija sukladno patentnom zahtjevu 4, naznačena time, da je 2 agonist salmeterol ksinafoat.
A pharmaceutical composition comprising a therapeutically effective amount of a compound according to paragraph 11 together with a pharmaceutically accepted carrier or excipient. 
Farmaceutski sastav, naznačen time, da obuhvaća terapeutski učinkovitu količinu spoja prema zahtjevu 17, zajedno s farmaceutski prikladnim nosačem ili pomoćnim sredstvom.
The composition of any of the preceding claims, wherein the improvement in at least one member selected from the group consisting of the social domain and the communication domain further includes a decrease in anxiety. 
Pripravak namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što poboljšavanje socijalnih vještina kod osobe uključuje poboljšavanje najmanje jednog člana kojeg se bira iz skupine koju čine socijaliziranje, prikladan odgovor na izgovoreni jezik, spontani pokušaji međudjelovanja, vizualni kontakt, raspoloženje, motiviranost i spokojnost.
The residue was taken up in ethylacetate (30ml) washed with 2NHCl (2x10ml) and then extracted with saturated sodium bicarbonate solution (2x15ml). 
Ostatak se preuzme u etil-acetat (30 ml), ispere s 2 N HCI (2 x 10 ml), te ekstrahira zasićenom otopinom natrijevog bikarbonata (2 x 15 ml).
Embodiment 13 The method of any of the foregoing Embodiments, wherein the effluent stream is cooled at about the same time that the sorbent particles are introduced into the effluent stream. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se izlazna struja ohladi istodobno s unošenjem čestica sorbensa u izlaznu struju.
maintaining the length of the large intestine and/or small intestine, such as preventing a reduction in the length of the large intestine and/or preventing an increase in the length of the small intestine; 
održavanje duljine debelog crijeva i/ili tankog crijeva kod subjekta, tako da se sprječava smanjenje duljine debelog crijeva i/ili sprječava povećanje duljine tankog crijeva,
The pharmaceutical composition as claimed in any of Claims 1 to 10, which is in form for oral administration, subcutaneous injection, intravenous injection, or intra-articular injection. 
Farmaceutski sastav za uporabu prema bilo kojem od zahtjeva 1 do 10, naznačen time, da je u obliku pogodnom za oralnu primjenu, za primjenu supkutanom injekcijom, za primjenu intravenoznom injekcijom ili za primjenu intraartikularnom injekcijom.
optionally coating the de novo papillae with extracellular matrix proteins, preferably collagen IV, fibronectin and/or laminin. 
(6) prevlačenja de novo papila sa izvanstaničnim matričnim proteinima, poželjno kolagenom IV, fibronektinom i/ili lamininom.
Said at least one carbodiimide may be N,N′-Dicyclohexylcarbodiimde (DDC), or 1-ethyl-3-(3-dimethyl amminopropyl) carbodimiide (EDC), such as in its hydrochloride form. 
Metoda u skladu sa patentnim zahtjevom 1 gdje navedeni najmanje kabodiimid je N, N'-Dicikloheksilkarbodiimid (DDC), ili 1 - etil-3-(3-dimetil aminopropil) karbodiimid (EDC), kao što je u njegovom hidroklorid obliku.
Use of the pharmaceutical composition according to any one of claims 1 to 12 as an anti-cancer vaccine. 
Farmaceutski sastav prema bilo kojem od zahtjeva 1 do 11 za uporabu kao cjepivo protiv karcinoma. t>&
In yet another aspect of the current invention, a method is presented for treating a condition such as transplantation rejection, host vs. graft disease, graft vs. host disease, leukemia, lymphoma, hyperproliferative vascular disorders, autoimmune disease, diseases of inflammation, solid tumors, and fungal infections in a patient, said method comprising administering a therapeutically effective amount of the aforementioned pharmaceutical composition to a patient in need thereof. 
U još jednom aspektu ovog izuma, predstavljen je postupak liječenja stanja kao što su odbacivanje transplantata, bolest host vs. graft, bolest graft vs. host, leukemija, limfom, hiperproliferativne vaskularne bolesti, autoimune bolesti, upalne bolesti, solidni tumori i gljivične infekcije pacijenata, pri čemu navedeni postupak obuhvaća primjenu terapijski djelotvorne količine prethodno spomenutog farmaceutskog pripravka u pacijenta kojem je takav tretman potreban.
A pyridazinone or pyridone compound of general formula (I'), or pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein 
Spoj piridazinona ili piridona opće formule (I’), ili njegova farmaceutski prikladna sol, hidrat ili solvat,gdje X je CH ili N;
The method of claim 1, wherein said antibody comprises a VH region comprising SEQ ID NO: 1 and a VL region comprising SEQ ID NO: 2. 
VH područje koje obuhvaća SEQ ID br. 1 i VL područje koje obuhvaća SEQ ID br. 2 [107];
An ODT as claimed in claim 1, wherein the at least one disintegrant is selected from the group consisting of crospovidone, sodium starch glycolate, crosslinked carboxymethyl cellulose, low-substituted hydroxylpropylcellulose, mannitol, xylitol, sorbitol, maltol, maltitol, lactose, sucrose, maltose, and combinations thereof. 
Tableta za oralno disperziranje sukladno patentnom zahtjevu 6, naznačeno time da je najmanje jedno sredstvo za razgradnju se bira iz skupine koju čine krospovidon, natrijev škrobni glikolat, umrežene karboksimetil celuloze, nisko supstituiran hidroksilpropil celuloza, manitol, ksilitol, sorbitol, maltol, maltitol, laktoza, saharoza, maltoza, i njihove kombinacije.
The use of the acid compound of Claim 9 wherein said select acid compound is sulphur, which ionizes within said sewage water stream to produce dissolved sulphur dioxide (SO2). 
Korištenje spoja kiseline prema zahtjevu 9, pri čemu je odabran spoj kiseline sumpor, koji ionizira unutar navedenog toka otpadne vode kako bi proizveo otopljen sumporov dioksid (SO>).
when R2 represents a group of formula (Ia), reacting a compound of formula (II) wherein j, X1, X2, R1, R3, R4, R5 and R7 are as defined in claim 1, with a compound of formula (III), R6-OH, where R6 is as defined in claim 1; or 
kada R2 predstavlja skupinu sa formulom (Ia), reakciju spoja sa formulom(II) [image] pri čemu j, X1, X2, R1, R3, R4, R5 i R7 su kako je definirano u zahtjevu 1, sa spojem sa formulom(III), R6-OH, gdje R6 je kako je definirano u zahtjevu 1; ili
Y represents a group of formula wherein the left bond is attached to the A group and the right bond is attached to the R group; 
Y predstavlja skupinu formule KH pri čemu je lijeva veza priključena na skupinu A a desna veza je priključena na R skupinu;
6- tert -Butyl-4-hydroxypyridazin-3(2H)-one, and pharmaceutically acceptable salts thereof. 
-tert-Butil-4-hidroksipiridazin-3(2H)-on, i njihove farmaceutski prihvatljive soli.
is alkyl which may be substituted by A, cycloalkyl which may be substituted by A, alkenyl which may be substituted by A, alkynyl which may be substituted by A, halogen, cyano, aryl, a heterocyclic group, OR2, S(O)nR3 or NR4R5; 
() naznačen time, da je R! alkil koji može biti supstituiran sa A, cikloalkil koji može biti supstituiran sa A, alkenil koji može biti supstituiran sa A, alkinil koji može biti supstituiran sa A, halogen, cijano, aril, heterociklička skupina, OR", S(O),R*, NR*R';
The method of claims 1 to 3, wherein the reference value is dependent on features of the video stream. 
Postupak u skladu s patentnim zahtjevima 1 do 3, naznačen time što referentna vrijednost ovisi o značajkama video toka.
The compound of Claim 2, wherein: 
Spoj predstavljen slijedećom strukturnom formulom:
The compound for use according to claim 1, wherein said compound has formula (VII): 
Spoj prema zahtjevu 1, pri čemu navedeni spoj ima formulu (VII):
A method according to claim1, characterized in that the thickness of the layers of the insulation (13) of the voltage coil (10) decreases with the increase in their distance to the coil axis. 
Postupak prema zahtjevu 1, naznačen time, da se debljina slojeva izolacije (13) naponske navojnice (10) s povećanjem razmaka od osi navojnice, smanjuje.
Also, the compound (I) was considered to be useful in the treatment and/or prevention of anxiety disorders, including panic disorders and generalized anxiety disorders. 
X KAT (ic) ili njegova farmaceutski prihvatljiva sol, pri čemu se on/ona upotrebljava u liječenju i/ili _profilaksi poremećaja anksioznosti.
A medication delivery device according to claim 1, arranged in the form of an electronic injection device adapted to inject medication through the skin of a patient. 
Sukladno bilo kojoj od zaštita 1-6, uređaj za davanje lijeka je naznačen time što se sastoji od elektronskog uređaja za ubrizgavanje konstruiranog za ubrizgavanje lijeka kroz bolesnikovu kožu.
The use according to Claim 61, wherein the diseases or disorders are bulimia, obesity or any disease resulting in the patient becoming overweight. 
Primjena prema Zahtjevu 61, naznačena time, da su bolesti ili poremećaji bulimija, gojaznost ili bilo koja bolest koja rezultira u prekomjernoj masi bolesnika.
comparing the activity of the CFTR or a fragment thereof in the presence of the additional compound with the activity of the CFTR or a fragment thereof in the presence of said composition comprising a compound of Formula I, according to claim 1. 
usporedbu aktivnosti CFTR ili njegovog fragmenta u prisutnosti dodatnog spoja s aktivnošću CFTR ili s njegovim fragmentom u prisutnosti navedenog pripravka spoja formule I, prema zahtjevu 1.
Example of the certificate of analysis of each plant 
Datum objave europske prijave patenta:
The antisense compound for use according to claim 7, or the use of an antisense compound according to claim 7, wherein the dose is: 
Protusmisleni spoj za uporabu prema patentnom zahtjevu 4. ili uporaba protusmislenog spoja prema patentnom zahtjevu 4, naznačena time što je doza:
This produces a homogeneous yarn with a high degree of elasticity, which in overall elasticity extensively corresponds to the elasticity of the elastic core filament. 
To stvara homogenu nit s visokim stupnjem elastičnosti, pri čemu ukupna elastičnost u velikoj mjeri odgovara elastičnosti središnje niti.
• externally, on its bottom part, a cylindrical section of a smaller diameter, with O-rings (33) and a connection nozzle (35) positioned at its free end, 
izvana, na svom donjem dijelu, valjkasti dio manjeg promjera, s O-prstenima (33) i spojnu mlaznicu (35), koja se nalazi na njegovom slobodnom kraju; i *
Thermoplastic polyalkylene oxides, such as polyethylene oxides, with a molecular weight of at least 0.5 million, preferably of up to 15 million, determined by rheological measurements, are very particularly preferred. 
Preferira se visokomolekularne, termoplastične polialkilenokside. Osobito se preferira visokomolekularne polietilenokside s molekularnom težinom od najmanje 0,5 milijuna, prvenstveno najmanje 1 milijun do 15 milijuna, određeno reološkim mjerenjima.
a heavy and/or light chain comprising the amino acid sequence of SEQ ID NO: 46, or SEQ ID NO:48, 60, 62, or 64, respectively; or 
teški i/ili laki lanac koji sadrži aminokiselinski slijed sa SEQ ID NO:46 odnosno SEQ ID NO:48, 60, 62 ili 64; ili
The composition of claim 1, wherein the functional nucleic acid molecule targets the transcript of MRP2, BCR-ABL, STI-571 resistance-associated protein, lung resistance-related protein, cyclooxygenase-2, nuclear factor kappa, XRCC1, ERCC1, GSTP1, mutant B-tubulin, or a growth factor. 
Sastav zahtjeva 3, time naznačeno da je protein MRP2, BCR-ABL, STI-571 povezan sa stvaranjem otpornosti, LRP (lung resistance related protein), ciklooksigenaza-2, nuklearni čimbenik kapa, XRCC1, ERCC1, GSTP1, mutant B-tubulin ili čimbenik rasta.
The method according to claim 15, wherein the phosphate compound is any one of the following: ammonium phosphate, potassium phosphate, and sodium phosphate. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da kemijsko sredstvo za usporavanje plamena sadržava fosfatni spoj, na primjer amonijev fosfat.
The pharmaceutical composition of clause 6, wherein the composition is administered by a method selected from the group consisting of oral, sublingual, buccal, parenteral, intravenous, transdermal, inhalation, intranasal, vaginal, intramuscular, and rectal modes of administration. 
Farmaceutska kompozicija prema patentnom zahtjevu 8, u obliku kapsule, granule, praha, otopine, suspenzije ili tablete i koja je dizajnirana za primjenu oralnim, sublingvalnim, bukalnim, parenteralnim, intravenskim, transdermalnim, inhalacionim, intranazalnim, vaginalnim, intramuskularnim ili rektalnim načinom.
is hydrogen; alkyl; hydroxy; mercapto; alkyloxy optionally substituted with amino or mono or di(alkyl)amino or a radical of formula 
R* je vodik; alkil; hidroksi; merkapto; alkiloksi proizvoljno supstituiran sa amino ili mono ili di(alkiljamino ili radikal sa formulom
The rotary machine according to claim 9, wherein the machine comprises at least two of said mechanisms (1) wherein the pendulum (4) of each support of each of said two mechanisms is placed in parallel and synchronised. 
Rotacijski stroj prema zahtjevu 9 naznačen time da se stroj sastoji od barem dva mehanizama (1) s polugom (4) poredanih paralelno i sinkroniziranih.
denotes Cl, Br, I or a free or reactively functionally modified OH group, is reacted with a compound of the formula V R1-NH2 V 
označava Cl, Br, I ili slobodnu ili reaktivno funkcionalno modificiranu OH skupinu, reagira sa spojem s formulom V
Z represents a capture tag, which is a C8-24 alkyl residue, a perfluoroalkyl entity, an azide or an alkynyl group, 
Z predstavlja oznaku za hvatanje, koja je Cg_24 alkilni ostatak, perfluoroalkil skupina, azid ili alkinil skupina,
The apparatus of claim 13 wherein the fluid container size is in the range of a fraction of a liter to several liters in volume. 
Sustav prema zahtjevu 16, naznačen time što je veličina posude za fluid u opsegu od dijela jedne litre do nekoliko litara volumena.